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Abstract
Breast carcinoma is the most common malignancy among women and it has a major impact on
mortality. Studies of primary chemoprevention with tamoxifen have generated high expectations
and considerable success rates. The efficacy of lower doses of tamoxifen is similar to that seen with
a standard dose of the drug, and there has been a reduction in healthcare costs and side effects.
The immune reaction to monoclonal antibody Ki-67 (MIB-1) and the expression of estrogen
receptors (1D5) and progesterone receptors (PgR 636) in breast carcinoma were studied in
patients treated with 10 mg of tamoxifen for a period of 14 days.
A prospective randomized clinical trial was conducted with 38 patients divided into two groups:
Group A: N = 20 (control group-without medication) and Group B: N = 18 (tamoxifen/10 mg/day
for 14 days). All patients signed an informed consent term previously approved by both institutions.
Patients underwent incisional biopsy before treatment and 14 days later a tumor tissue sample was
obtained during surgical treatment. Positivity was quantitatively assessed, counting at least 1.000
cells per slide. For statistical data analysis, a Wilcoxon non-parametric test was used, and α was set
at 5%.
Both groups (A and B) were considered homogeneous regarding control variables. In Group A
(control), there was no statistically significant reduction in Ki-67 (MIB-1) (p = 0.627), estrogen
receptor (1D5) (p = 0.296) and progesterone receptor positivity (PgR 636) (p = 0.381).
In Group B (tamoxifen 10 mg/day), the mean percentage of nuclei stained by Ki-67 (MIB-1) was
24.69% before and 10.43% after tamoxifen treatment. Mean percentage of nuclei stained by
estrogen receptor (1D5) was 59.53% before and 25.99% after tamoxifen treatment. Mean
percentage of nuclei stained by progesterone receptor (PgR 636), was 59.34 before and 29.59%
after tamoxifen treatment. A statistically significant reduction was found with the three markers (p
< 0.001).
Tamoxifen significantly reduced monoclonal antibody Ki-67 (MIB-1), estrogen receptor (1D5) and
progesterone receptor positivity (PgR 636) in the breast epithelium of carcinoma patients treated
with a 10 mg dose of tamoxifen for 14 days.
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Background
Chemoprophylaxis of breast carcinoma with tamoxifen in
women at increased risk for breast cancer has produced
encouraging results. Studies of primary chemoprevention
with tamoxifen in usual doses have generated high expec-
tations with a 50% reduction in the relative risk for inva-
sive carcinoma in high-risk patients [1]. Some evidence
indicates that tamoxifen dose can be lowered to reduce its
side-effects and retain drug efficacy [1-3].
Tamoxifen and similar drugs act in a complex manner as
estrogen antagonists in tumor tissue, and as estrogen ago-
nists in other body tissues, including the bones, uterus
and cardiovascular system. The drug's action is mediated
by cell estrogen receptor through various complex reac-
tions [4-13].
Alfa estrogen receptor (ERα), located on chromosome 6 is
a protein comprising 595 aminoacids, with a molecular
weight of 66 kDa. Therefore, similar to other hormone
receptors, the estrogen receptor is a modulated protein
that can be divided into six different domains (A-B-C-D-
E-F) with specific functions [7,14].
Recently, a second receptor named beta (ERβ) was discov-
ered. It is homologous to ERα and located on chromo-
some 14, comprising 485 aminoacids with a molecular
weight of 54.2 kDa. Estrogen receptors α and β have
homologous proteins in different domains [7,14].
Estrogen exerts a regulating effect on progesterone recep-
tor, which is synthesized in response to estrogen action.
The presence of progesterone receptor directly reflects acti-
vation and gene transcription of estrogen receptor, and is
useful for evaluating the prognosis of tumor cells [15].
Human progesterone receptor gene is located on chromo-
some 11q22-23. Several different types of isoforms, par-
ticularly progesterone receptor A and B, have been well
characterized and studied [16].
Progesterone receptor B is longer with 933 aminoacids,
having a molecular weight of 114 kDa and five domains
(A, B, C, D and E). Progesterone receptor A is shorter with
769 aminoacids, having a molecular weight of 94 kDa and
also five domains (A, B, C, D and E) [17].
Other progesterone receptor variants are cited, including
C, S and T [18,19].
Isoforms A and B of the progesterone receptor are func-
tionally different and responsible for diverse physiologi-
cal effects on different target tissues. However, these
effects are not yet fully understood [17].
Ki-67 is a widely used antibody which reacts with a
nuclear nonhistone protein (antigen). Ki-67 antigen is
revealed as a double band with apparent molecular
weights of 395 and 345 KD and is regulated by a gene
located on chromosome 10 [21-26].
To evaluate the use of low-dose tamoxifen, we proposed
this clinical trial administering tamoxifen at a dose of 10
mg/day for 14 days in the neoadjuvant treatment of inva-
sive breast carcinoma.
Patients and methods
Patients
A prospective randomized clinical trial of 38 patients with
invasive breast carcinoma was conducted at the Outpa-
tient Facility of the Division of Breast Diseases, HMI,
Goiânia, Brazil, and Division of Breast Diseases of the
Federal University of São Paulo (UNIFESP), São Paulo,
Brazil.
Women with palpable and operable breast tumors, stages
I, II and IIIA participated in the study. Diagnosis had been
confirmed by clinical exam, mammography and cytology
positive for breast cancer.
Excluded from the study were women with tumors eligi-
ble for chemotherapy; neoadjuvant endocrine therapy;
history of thromboembolism and breast cancer in the
pregnancy-puerperal cycle; and previous biopsy of the
breast lesion.
Patients were distributed into two research groups accord-
ing to the randomized study. Group A, with 20 patients
(control) and Group B, with 18 patients (tamoxifen 10
mg/day)
Patients in Group B (tamoxifen 10 mg) were advised to
start medication on the day biopsy was performed for
diagnostic confirmation, and continue for 14 days until
the date of definitive surgery. Tamoxifen was adminis-
tered at a dose of 10 mg once a day, always at the same
time.
Similarly, Group A (control) patients underwent diagnos-
tic biopsy. After 14 days, these patients returned for defin-
itive surgery.
At the time of incisional biopsy, a sample of the tumor
was fixed in 10% formalin and paraffin-embedded for
diagnostic confirmation, as recommended by the World
Health Organization. Another fragment was fixed sepa-
rately in buffered formalin for less than 24 hours. During
definitive surgery (mastectomy or quadrantectomy), a
new tumor fragment was removed contralateral to the first
sample collected, to avoid areas of necrosis. This fragmentInternational Seminars in Surgical Oncology 2006, 3:29 http://www.issoonline.com/content/3/1/29
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was fixed in buffered formalin. The remaining material
was fixed in 10% formalin prior to paraffin processing
and routine evaluation.
Histopathological method
The breast tissue obtained was fixed in 10% buffered for-
malin for a maximum period of 24 hours prior to routine
paraffin processing. Specimens were serially trimmed into
slices of approximately three to four micrometers and
mounted on slides stained by the hematoxylin-eosin tech-
nique for histopathology study.
The 10% buffered formalin solution was prepared by add-
ing 100 ml formaldehyde (in a 35–40% solution) p.a., 4
g monohydrated sodium phosphate monobasic
(NaH2P04.H2O), 6 g sodium phosphate dibasic anhy-
drous p.a (Na2HP04) and 1000 ml distilled water q.s.p.
Immunohistochemical method
Tissue blocks of 4 to 5 μm thickness were cut with a micro-
tome and prepared on silanized slides.
Tissue sections were deparaffinized with hot xylol at 60°C
for 15 minutes at room temperature during more than 15
minutes. Histologic sections were then hydrated in
decreasing concentrations of alcohol (100, 95, 80 and
70%) for 30 seconds each and rinsed in distilled tap
water.
Antigen retrieval was then mediated by humid heat (water
bath FANEN Mod. BM – 147, series RX 4614), submerg-
ing the slides in a buffer sodium citrate solution 10 mMol,
pH 6.0, during five minutes [27].
Subsequently, the slides were cooled at room temperature
and rinsed in tap water. Endogeneous peroxide block was
performed with 0.3% oxygenated water (diluted in meth-
anol) in three baths of five minutes each. Then slides were
rinsed in distilled tap water and in PBS buffer (buffered
saline solution with 0.01 M and pH 7.4 to 7.6).
Incubation with primary monoclonal antibody Ki-67 was
then performed (clone MIB-1) DAKO, code N° M7240,
batch 012, diluted to 1/150, at 4°C overnight, followed
by rinsing in PBS solution.
Bacteria were then incubated with monoclonal antibody
specific for estrogen receptor α, DAKO clone 1D5, code
N° M7047, batch 070, diluted to 1:250.
Another batch of bacteria was sequentially incubated with
monoclonal antibody specific for progesterone receptor,
DAKO clone PgR 636, code N° M3569, batch 532, diluted
to 1:650.
The next step was to visualize the reaction with chro-
mogen substrate 3-3' diaminobenzidine DAB (0.06 g DAB
and 1 ml H2O2 20 volumes) for three to five minutes at
37°C, completely covered to protect from light. On
microscopy, a dark brown precipitation was observed,
after rinsing under distilled tap water.
Sections were counterstained with Harris hematoxylin for
one minute. The slides were then immersed in ammonia-
cal water and rinsed under distilled tap water.
Subsequently, the slides were dehydrated using alcohol
(at 70, 80, 95 and 100% concentrations) three times for
one minute each and diaphanized in three xylol baths for
one minute each. Slides and coverslips were mounted
with balsam (Entellan®).
Quantitative study
The immune reaction of Ki-67 (MIB-1), estrogen receptor
(1D5) and progesterone receptor (PgR 636) was quantita-
tively evaluated by counting a minimum of 1.000 cells
[19]. The percentage of immune reaction in each case was
obtained from the relationship between stained and
unstained cells multiplied by 100. Only the epithelial
tumor element of the sample was evaluated. The stromal
element was excluded.
For the study, an image digital analysis system was used,
consisting of a NIKON JAPAN LABOPHOT-2 microscope,
series n° 440021, with a NIKON objective lens of 40×,
attached to a color digital video camera SDC-312ND
POWER: DC12 V 3 W SAMSUNG TECHWIN CO LTD
series N° R4602662, to import images into an AUTHEN-
TIC AMD microcomputer with an AMD DURON proces-
sor (tm) and 128.0 MB RAM and 40 GB HD; equipped
with a digitized plate, with software WinTV32 and Win-
dows Paint in Windows 98 Immune reaction was evalu-
ated by an objective lens of 40× (final magnification of
400×) in 15 to 20 fields per case, categorizing as positive
the cell with a typical brown nucleus.
Statistical analysis
Analysis of variance was employed (ANOVA) to compare
quantitative variables (age, menarche, tumor size and his-
tologic grade) and evaluate homogeneity between Groups
A (control) and B (tamoxifen 10 mg/day) [28,29].
A Kruskal-Wallis non-parametric test was used to evaluate
homogeneity between Groups A and B, regarding varia-
bles (number of pregnancies, deliveries, abortions, classi-
fication by BI-RADS System, quadrant location of tumor,
number of positive lymph nodes, total number of axillary
lymph nodes and clinical staging) [30].International Seminars in Surgical Oncology 2006, 3:29 http://www.issoonline.com/content/3/1/29
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Fisher's exact test was employed to evaluate homogeneity
between Groups A and B, regarding variables such as pre-
vious family history of breast cancer in first- degree rela-
tive, menopausal status, laterality and type of surgery [28].
A comparison between both Groups A and B regarding Ki-
67 (MIB-1), estrogen receptor (ID5) and progesterone
receptor positivity (PgR 636) before treatment was ana-
lyzed by the Mann-Whitney test [30].
The Wilcoxon non-parametric test was used to compare
equality in mean expression of Ki-67 (MIB-1), estrogen
receptor (1D5) and progesterone receptor (PgR 636) of
Groups A and B, before and after tamoxifen therapy
[30,31].
The level of significance was set at 5% (α<5%) in all tests
and significant values were marked with an asterisk.
Results
The mean percentage of nuclei stained by Ki-67 (MIB-1)
in Group B (10 mg of tamoxifen) before and after
tamoxifen treatment was 24.69% and 10.43%, respec-
tively. Reduction was statistically significant (p < 0.001)
(Table 4 and Figure 4).
The mean percentage of nuclei stained by estrogen recep-
tor (clone 1D5) in Group B (10 mg tamoxifen) before and
after tamoxifen treatment was 59.53% and 25.99%,
respectively. A statistically significant reduction was
observed (p < 0.001) (Table 5 and Figure 5).
The mean percentage of nuclei stained by progesterone
receptor (PgR 636) in Group B (tamoxifen 10 mg) before
and after tamoxifen treatment was 59.34% and 29.59%,
respectively. Reduction was statistically significant (p <
0.001) (Table 6 and Figure 6).
In Group A (control), there was no statistically significant
decrease in Ki-67 (MIB-1) (p = 0.627), estrogen receptor
(1D5) (p = 0.296) and progesterone receptor (PgR 636)
positivity (p = 0.381) (Tables 1, 2 and 3, Figures 1, 2, 3).
Both groups (A and B) were considered homogeneous
before treatment, regarding Ki-67 (MIB-1) (p = 0.838),
estrogen receptor (ID5) (p = 0.737) and progesterone
receptor positivity (PgR 636) (p = 0.704).
Groups A and B were considered homogeneous regarding
the following control variables: age (p = 0.481), age at
menarche (p = 0.182), tumor size (p = 0.145) and histo-
logic grade (p = 0.069), number of pregnancies (p =
1.000), deliveries (p = 0.857), abortions (p = 0.850), clas-
sification in the BI-RADS System (p = 0.544), quadrant
location of tumor (p = 0.667), number of lymph nodes
involved (p = 0.542), total number of dissected lymph
nodes (p = 0.988), clinical staging (p = 0.368), previous
family history of breast cancer in first-degree relative (p =
0.526), menopausal status (p = 0.159), laterality (p =
0.248) and type of surgery performed-mastectomy or
quadrantectomy (p = 0.255).
In Group A (control), the usual infiltrating ductal carci-
noma was the histologic variety in 100% of the cases,
while in Group B (tamoxifen at 10 mg/day), infiltrating
ductal carcinoma was predominant in 16 cases (90.0%).
Only one case of mucinous carcinoma (5.0%) and one
case of undifferentiated neuroendocrine carcinoma
(5.0%) was observed.
Discussion
Tamoxifen, a selective estrogen receptor modulator
(SERM), is the standard drug for endocrine therapy in
patients with estradiol and/or progesterone receptor posi-
tive breast cancer [1,4,35,38,39].
The response of estrogen-receptor positive tumors to hor-
monal therapy ranges from 30 to 60%, reaching 80%
when there is concomitant positivity for both estrogen
and progesterone receptors [34-36].
Interaction between growth factors and tamoxifen may
lead to inhibition of cell proliferation in both receptor
positive and receptor negative tumors. TGF-α inhibition
and stimulation of TGF-β production is observed. In cell
culture with estrogen positive receptors, TGF-β activation
may occur through an autocrine loop. Nevertheless, in cell
culture with estrogen negative receptors TGF-β might exert
paracrine function, regulating proliferation adjacent to
neoplastic cells [2,6,33,36,37].
Breast cancer is a hormone dependent malignancy. How-
ever, Beattie et al. (2006) observed that in the postmeno-
pause there is no association between levels of estradiol,
testosterone and SHBG (Sex Hormone-Binding Globulin) in
patients with breast cancer compared to healthy women.
Measurements of these sex hormones should not be used
to identify women at risk for treatment or chemopreven-
tion with tamoxifen [40].
In the past, tamoxifen was used in daily doses of 30 and
40 mg for treatment of advanced breast cancer. Subse-
quently, the dose was empirically reduced to 20 mg/day to
decrease toxicity [2-4,37,41].
Uehara [42] evaluated estrogen and progesterone receptor
positivity in invasive breast carcinoma in women receiv-
ing tamoxifen at a dose of 20 mg/day for two and 14 days.
He observed a significant decrease in these receptors when
tamoxifen was administered for 14 days. However, heInternational Seminars in Surgical Oncology 2006, 3:29 http://www.issoonline.com/content/3/1/29
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found no significant difference when the drug was used
for two days. These data suggest that 20 mg should be the
empirical dose, since length of drug use was a greater
determinant of decrease in tumoral proliferation than
tamoxifen dose.
In a randomized, double-blind study, Decensi et al. [2]
used tamoxifen in 120 women with hormone receptor
positive breast cancer and observed a similar decrease in
Ki-67 positivity with doses of 1, 5 and 20 mg/day for 28
days. In this study, the pharmacodynamic effect of these
Table 2: Percentage of nuclei stained by estrogen receptor (1D5) in Group A (Control) before and after 14 days (magnified 400×).
PATIENT Control (before) (% stained cells) Control (after 14 days) (% stained cells)
1 45.61 33.82
2 46.31 33.45
3 25.63 30.48
4 47.41 44.82
5 60.63 55.96
6 33.89 48.78
7 88.92 90.81
8 33.59 29.51
9 30.25 14.65
10 15.47 25.26
11 30.12 22.23
12 100.00 97.01
13 81.12 80.58
14 51.25 53.69
15 16.05 20.15
16 95.87 98.79
17 80.56 75.89
18 45.06 22.79
19 89.07 90.46
20 98.19 98.89
MEAN 55.75 53.40
Table 1: Percentage of nuclei stained by ki-67 (clone MIB-1) in Group A (control) before and after 14 days (magnification 400×).
PATIENT Control (before) (% stained cells) Control (after 14 days) (% stained cells)
1 29.31 26.12
2 30.83 31.24
3 75.35 69.56
4 28.17 5.68
5 28.39 25.30
6 42.60 40.51
7 20.32 25.63
8 49.25 50.01
9 50.39 52.18
10 70.21 68.92
11 21.52 30.61
12 10.52 5.23
13 2.14 5.76
14 1.23 1.52
15 90.54 81.87
16 2.36 3.49
17 0.25 0.36
18 32.56 36.48
19 2.56 4.89
20 12.62 8.98
MEAN 30.06 28.72International Seminars in Surgical Oncology 2006, 3:29 http://www.issoonline.com/content/3/1/29
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three different doses of tamoxifen was evaluated. A dose-
response relationship was observed between several cardi-
ovascular risk factors, such as concentration of total cho-
lesterol, low density lipoprotein (LDL), insulinoid growth
factor (IGF-1), fibrinogen, antithrombin III and SHBG.
There was no substantial modulation of these risk factors.
Results indicated that the conventional dose of 20 mg/day
may be higher than the minimum dose necessary for the
biological activity of tamoxifen. Lower doses would likely
be sufficient to obtain an antiproliferative effect.
At the same time, Rodrigues de Lima et al. [4] observed a
similar reduction in positivity of estrogen and progester-
one receptors, Ki-67, apoptosis and mitotic index in nor-
mal breast epithelium with tamoxifen doses of 5, 10 or 20
mg/day.
Box-plots for mean estrogen receptor variable (1D5) in  Group A (control) before and after 14 days Figure 2
Box-plots for mean estrogen receptor variable (1D5) in 
Group A (control) before and after 14 days.
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Table 3: Percentage of nuclei stained by progesterone receptor (PgR 636) in Group A (Control) before and after 14 days (magnified 
400×).
PATIENT Control (before) (% stained cells) Control (after 14 days) (% stained cells)
1 49.92 26.45
2 63.51 70.84
3 33.56 25.98
4 98.71 90.29
5 85.59 78.36
6 66.89 71.24
7 78.42 77.25
8 50.14 45.89
9 0.00 0.00
10 16.52 14.81
11 0.00 0.00
12 100.00 98.89
13 95.12 96.48
14 91.24 78.25
15 17.85 19.25
16 80.13 85.64
17 25.36 22.84
18 15.12 20.98
19 22.05 26.97
20 100.00 100.00
MEAN 54.51 52.52
Box-plots for mean Ki-67 variable (MIB-1) in Group A (con- trol) before and 14 days Figure 1
Box-plots for mean Ki-67 variable (MIB-1) in Group A (con-
trol) before and 14 days.
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In the following year, Kisanga et al. [41] evaluated Ki-67
variation after tamoxifen treatment during 28 days, using
doses of 1, 5 and 20 mg/day. A significant reduction in Ki-
67 was observed with the three different doses compared
to the placebo group. There was a similar reduction using
the three doses. Such evidence indicates that tamoxifen
dose could be reduced without damage to its efficacy and
with a decrease in side effects.
Such studies prompted us to set up this research project.
Thus, a prospective, randomized clinical trial was carried
out in breast cancer patients, using tamoxifen at a dose of
10 mg/day for 14 days. The study was simultaneously con-
trolled by a group that did not receive drugs. The aim of
the study was to evaluate effects specific to surgical inter-
vention before and after 14 days of drug use, since com-
plications including hematoma, inflammation, infection,
use of anesthetics and other drugs are inherent in the pro-
cedure.
Randomization was adequate, because the control varia-
bles were uniform in both groups. There was no signifi-
cant reduction in immunoreaction of the markers studied
in the control group (without drug), showing that even-
tual complications from the surgical procedure did not
hinder data analysis.
We emphasize that the microscope slides were examined
and read twice by the research author. Control was sup-
plied by a medical pathologist with proven experience in
breast pathology. We also highlight that the three markers
were studied for all 38 patients, six slides per patient,
before and after treatment. For each slide, from 15 to 20
fields were selected counting at least 1000 cells, making
6.000 cells per patient.
The percentage of stained nuclei in Group B (tamoxifen –
10 mg/day) for the Ki-67 monoclonal antibody (MIB-1)
before and after 14 days of drug use was 24.7% and
10.4%, respectively, showing a significant reduction.
Table 4: Percentage of nuclei stained by Ki-67 (MIB-1) in Group B (tamoxifen 10 mg) before and after 14 days of drug use (magnified 
400×).
PATIENT Before tamoxifen 10 mg (% stained cells) 14 days after tamoxifen 10 mg (% stained cells)
1 8.82 1.70
2 33.79 10.54
3 6.51 5.52
4 29.07 12.62
5 53.32 28.06
6 17.58 8.77
7 12.48 1.27
8 21.05 13.15
9 24.87 2.86
10 11.22 7.95
11 29.45 16.25
12 45.90 6.80
13 24.25 8.29
14 43.56 20.32
15 5.35 3.45
16 2.26 1.75
17 51.40 34.30
18 23.50 4.10
MEAN 24.69 10.43
Box-plots for mean progesterone receptor variable (PgR  636) in Group A (control) before and after 14 days Figure 3
Box-plots for mean progesterone receptor variable (PgR 
636) in Group A (control) before and after 14 days.
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The same occurred for the estrogen receptor, 59.5% before
and 25.9% after drug use, and progesterone receptor,
59.34% and 29.6%, respectively. Both showed a signifi-
cant reduction. Biomarker results suggest that lower
tamoxifen doses produce results similar to those of the
standard dose. If applied to clinical trials, such findings
may lead to a significant reduction in costs and less side
effects.
Our results are similar to those of Uehara [42], who also
evaluated estrogen and progesterone receptor positivity in
breast cancer of women treated with tamoxifen. However,
tamoxifen was used at a 20 mg/day dose for 14 days. The
mentioned author observed a ratio reduction from 55.4%
to 10.2% in cells stained for estrogen receptors, and from
59.2% to 18.9% in those stained for progesterone recep-
tors. In a similar manner, using a 10 mg/day dose of the
drug for 14 days, our data revealed a reduction from
59.5% to 25.9% and from 59.3% to 29.6% for estrogen
and progesterone receptors, respectively.
Likewise, results obtained by Decensi et al. [2] demon-
strated that use of 1, 5 or 20 mg/day dose of tamoxifen for
four weeks, lead to a similar reduction in proliferative
activity of breast carcinoma, evaluated by Ki-67 mono-
clonal antibody. In the group using a tamoxifen dose of 1
mg/day, 4-hydroxytamoxifen metabolite level was 10–20
times higher than the minimum inhibitory concentration.
In the current study, the percentage of nuclei stained by
Ki-67 monoclonal antibody after using 10 mg/day of
tamoxifen for 14 days decreased from 24.7% to 10.4%.
Consistent with this result, Descensi et al. [2] obtained a
21.2% to 14.0% decrease in nuclei staining, demonstrat-
ing that our results are similar to those obtained by the
above-mentioned authors.
Our results showed that using 10 mg/day of tamoxifen for
14 days is enough to reduce proliferative activity. Descensi
et al. [2] described that this activity was similarly reduced
Table 5: Percentage of nuclei stained by estrogen receptor (1D5) in Group B (tamoxifen 10 mg) before and after 14 days of drug use 
(magnified 400×).
PATIENT Before tamoxifen 10 mg (% stained cells) 14 days after tamoxifen 10 mg (% stained cells)
1 68.59 30.25
2 45.68 12.47
3 69.48 26.56
4 55.26 12.56
5 0.00 0.00
6 68.67 26.11
7 71.39 10.58
8 74.37 55.42
9 94.96 27.85
10 70.87 20.32
11 100.00 81.32
12 25.63 13.58
13 10.25 2.25
14 92.54 32.38
15 21.21 4.29
16 100.00 50.26
17 14.15 5.58
18 88.59 56.21
MEAN 59.53 25.99
Box-plots for mean Ki-67 variables (MIB-1) in Group B  (tamoxifen 10 mg) before and 14 days of treatment Figure 4
Box-plots for mean Ki-67 variables (MIB-1) in Group B 
(tamoxifen 10 mg) before and 14 days of treatment.
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at doses of 1, 5 or 20 mg/day. The decrease in estrogen and
progesterone receptor positivity in this study, at 10 mg/
day of tamoxifen for 14 days was similar to that observed
by Uehara [42] at 20 mg/day of tamoxifen for 14 days.
A limitation to the current study was not having used a
group treated with 20 mg/day of tamoxifen. Future
research should be undertaken to compare five rand-
omized groups, using placebo or 1, 5, 10 and 20 mg of the
drug.
The current study is a pilot project of a research line con-
ducted in the Discipline of Breast Pathology at the Depart-
ment of Gynecology of UNIFESP-EPM, apart from other
studies that have already been published. It demonstrated
efficacy in vivo of tamoxifen used at a low dose. From these
data, we can propose studies into the effect of low-dose
tamoxifen on the adjuvant and neoadjuvant therapy of
breast cancer.
Although tamoxifen has been in clinical use for over 30
years in oncology, little is known about the minimum
effective dose of the drug. This was probably due to the
low number of adverse effects observed with the usual
dose.
Recent studies employing aromatase inhibitors have dem-
onstrated encouraging results with an improvement of
disease-free survival, when compared to those using
tamoxifen.
In the IMPACT (Immediate Preoperative Anastrozole,
Tamoxifen or Anastrozole Combined with Tamoxifen) study,
292 women were randomized into three groups, anastro-
zol (n = 98), tamoxifen (n = 98), anastrozol combined
with tamoxifen (n = 96) for neoadjuvant treatment of
breast cancer. The authors observed a significant reduc-
tion in Ki-67 positivity, greater in anastrozol users than in
Table 6: Percentage of nuclei stained by progesterone receptor (PgR 636) in Group B (tamoxifen 10 mg) before and after 14 days of 
drug use (magnified 400×).
PATIENT Before tamoxifen 10 mg (% stained cells) 14 days after tamoxifen 10 mg (% stained cells)
1 89.63 48.26
2 85.62 56.21
3 15.62 20.34
4 65.49 49.25
5 25.64 2.45
6 50.47 9.87
7 85.49 30.58
8 55.21 41.59
9 0.00 0.00
10 71.64 24.47
11 2.87 0.00
12 100.00 48.47
13 63.98 53.41
14 60.32 25.48
15 20.29 2.45
16 98.79 48.78
17 89.64 26.98
18 87.49 44.15
MEAN 59.34 29.59
Box-plots for mean estrogen receptor variable (1D5) in  Group B (tamoxifen 10 mg) before and after 14 days of treat- ment Figure 5
Box-plots for mean estrogen receptor variable (1D5) in 
Group B (tamoxifen 10 mg) before and after 14 days of treat-
ment.
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tamoxifen users at a dose of 20 mg/day for 12 weeks.
However, suppression of cell proliferation was similar in
tamoxifen users versus users of tamoxifen combined with
anastrozol. The authors observed an increase in disease-
free survival in anastrozol users compared to tamoxifen
users. No difference in disease-free survival was found in
tamoxifen users versus users of tamoxifen combined with
anastrozol [43].
Despite the introduction of a new generation of drugs that
are ten times more expensive, tamoxifen still has a satis-
factory cost/benefit ratio. The drug is also of major impor-
tance in countries with public health policies.
The researcher has responsibility for investing in research
that may improve medical care of the low-income popu-
lation, in spite of commercial interests. Dose reduction
would be an important strategy for treatment in our set-
ting, increasing the number of women who would have
access to medication, with a minimum of side effects.
In addition to results obtained by other authors
[2,3,41,42], our results support the need to conduct clini-
cal trials on adjuvant therapy and chemoprevention with
low-dose tamoxifen, to provide comprehensive and low
cost medical care for women with breast cancer.
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